empty
 
 
rs
Search
Podrška
Trenutno otvaranje računa
Trgovačka platforma
Depozit/Povlačenje
Search
Za početnike Za trgovce Za partnere Idi na pauzu About InstaSpot
rs
#BGNE Nazad na listu instrumenata #BMY

Menjač valuta

Biogen Inc.
149.49 USD
10 Jan 2025 19:18
Promena cene (% chg)
$0.36
(0.24%)
Cena prethodnog zatvaranja
Cena prethodnog zatvaranja

Cena zatvaranja prethodnog dana.
$150.5
Otvaranje
Otvaranje

Cena na otvaranju.
$150.5
Dnevni maksimum
Dnevni maksimum

Najviša cena tokom poslednjeg dana trgovine.
$149.73
Dnevni minimum
Dnevni minimum

Najniža cena tokom poslednjeg dana trgovine
$147.4
Maksimum u 52 nedelje
Maksimum u 52 nedelje

Opseg najviših cena u poslednje 52 nedelje
$153.95
Minimum u 52 nedelje
Minimum u 52 nedelje

Opseg najnižinih cena u poslednje 52 nedelje
$147.4
Preuzmi arhivu
Buy
149.49
Sell
149.49
Otvori grafikon za pregled na celom ekranu
Buy
149.49
Sell
149.49
Preuzmi arhivu
Otvori grafikon za pregled na celom ekranu

Biogen Inc. About company

Biogen Inc. is an American biopharmaceutical company founded in 1978. Initially, the company was headquartered in Switzerland, with all studies being conducted in European countries. Later, most of the company’s research centers were moved to the United States.

Biogen Inc. is engaged in the production of drugs based on DNA studies. At present, the company produces drugs used to treat multiple sclerosis, SMA, Alzheimer's disease, and other disorders.

Biogen’s market cap is $38.33 billion. Last year, its annual revenue stood at $10.981 billion, with net income at $1.556 billion.

Biogen’s shares and factors affecting their value

Its stock has been listed on the NASDAQ exchange under the ticker BIIB since 1983. The initial share price was $23.

Today, the company's shares are worth $257-$267. Over the past year, their value has ranged from $187 to $291.

When trading Biogen’s stock, traders are recommended to keep track of:

  • The products manufactured by the drugmaker are in demand. Moreover, their relevance is bound to increase in the future due to the world's aging population as well as progressive diseases among the elderly;
  • If the company passes clinical trials and receives a patent for a drug, it provides itself with an opportunity to make profits for at least 12 years, while other companies are prohibited from releasing analogues;
  • If Aducanumab receives approval as a treatment for Alzheimer's disease, the company’s capitalization will increase several times;
  • The company has good prospects in the market as it is greatly underestimated in comparison to competitors.

Ne možete da razgovarate sada?
Postavite pitanje kroz ćaskanje.